Multifaceted hemolytic uremic syndrome in pediatrics.
Hemolytic uremic syndromes can have devastating consequences in childhood. The common feature of a microangiopathic hemolytic anemia and thrombocytopenia associated with varying degrees of renal injury often creates diagnostic confusion. The inability to arrive at a definitive diagnosis quickly can lead to a delay in initiating renal-preserving and sometimes life-saving treatment. Currently, both the treatment plan and the prognosis vary substantially according to the presumed diagnosis. The availability of anti-complement therapy makes differentiating the cause of the hemolytic uremic syndrome particularly critical. Therefore, it is imperative that consideration be given to each of the possible syndromes at presentation in order to facilitate correct diagnosis and development of an appropriate treatment strategy for both the acute phase and for the long-term care of the patient.
Departments of Internal Medicine and Pediatrics, Rare Renal Disease Clinic, University of Iowa, Iowa City, IA 52242-1081, USA. carla-nester@uiowa.edu
Carla M
CM
Nester
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D001803:Blood Transfusion; D002648:Child; D057210:Delayed Diagnosis; D003955:Diagnostic Tests, Routine; D003967:Diarrhea / Q000175:diagnosis / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D005440:Fluid Therapy; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008134:Long-Term Care; D011379:Prognosis; D017582:Renal Replacement Therapy; D054323:Shiga-Toxigenic Escherichia coli / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity
D000700:Analgesics; D000911:Antibodies, Monoclonal